SGMT (STOCKS)
Sagimet Biosciences Inc. Series A Common Stock
$9.280000
-0.110000 (-1.17%)
Prev close: $9.390000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- David A. Happel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $746.48M
- Employees
- 14
- P/E (TTM)
- -7.24
- P/B (TTM)
- 2.26
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
10
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.33 | $-0.38 | +0.0518 | +13.57% |
|
Dec 2025 (Q4)
|
$-0.29 | $-0.41 | +0.1249 | +30.10% |
|
Sep 2025 (Q3)
|
$-0.40 | $-0.39 | -0.0067 | -1.70% |
|
Jun 2025 (Q2)
|
$-0.32 | $-0.52 | +0.1976 | +38.18% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $52.63M |
| Research and Development | $34.99M |
| Other Operating Expenses | $17.64M |
| Operating Income/Loss | -$52.63M |
| Income/Loss From Continuing Operations After Tax | -$47.08M |
| Income/Loss From Continuing Operations Before Tax | -$47.08M |
| Net Income/Loss | -$47.08M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$47.08M |
| Net Income/Loss Available To Common Stockholders, Basic | -$47.08M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.29 |
| Diluted Earnings Per Share | -$1.29 |
| Basic Average Shares | 118,198,467 |
| Diluted Average Shares | 118,198,467 |
| Assets | $263.43M |
| Current Assets | $243.99M |
| Cash | $257.60M |
| Noncurrent Assets | $19.44M |
| Liabilities | $7.28M |
| Current Liabilities | $5.42M |
| Accounts Payable | $1.13M |
| Wages | $956.00K |
| Other Current Liabilities | $3.33M |
| Noncurrent Liabilities | $1.86M |
| Equity | $256.16M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $256.16M |
| Liabilities And Equity | $263.43M |
| Net Cash Flow From Operating Activities | -$41.72M |
| Net Cash Flow From Operating Activities, Continuing | -$41.72M |
| Net Cash Flow From Investing Activities | $629.00K |
| Net Cash Flow From Investing Activities, Continuing | $629.00K |
| Net Cash Flow From Financing Activities | $164.66M |
| Net Cash Flow From Financing Activities, Continuing | $164.66M |
| Net Cash Flow | $123.57M |
| Net Cash Flow, Continuing | $123.57M |
| Comprehensive Income/Loss | -$47.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$47.23M |
| Other Comprehensive Income/Loss | -$36.47M |